Comment on CMS-2026-2212-0001

Summary: Transparency Rising, representing companies in the pharmacy benefit management and prescription drug supply chain, submitted comments supporting a transparent and competitively neutral regulatory framework for Part D drug compensation. They provide technical input on definitions for PBMs, affiliates, and "bona fide service fees," while advocating for disclosure-based transparency and the use of existing industry data formats to reduce reporting burdens.